International Trademarks for Hemp‑THC and CBD Beverages: Madrid Strategy, Specimens, and the “Lawful Use” Trap (USPTO 2025–2026)

If you sell (or plan to sell) CBD drinks or hemp‑derived THC beverages, trademarks can feel like a simple branding step—until you run into the U.S. federal “lawful use in commerce” requirement. In 2025–2026, brand owners are still seeing USPTO refusals when the identified goods are considered unlawful under federal law, even if the product is widely sold under certain state frameworks.

This article explains how beverage brands are using the Madrid Protocol to build international protection, how to avoid common specimen pitfalls, and how to plan filings so you don’t accidentally lock yourself into an unregistrable U.S. position. It’s informational only, not legal advice.

The “lawful use” trap: why beverage marks get refused in the U.S.

U.S. federal trademark registration is tied to use in commerce that must be lawful under federal law. The USPTO applies this doctrine through examining attorney refusals and TTAB precedent when the application record indicates a per se federal law violation.

Two federal frameworks drive most beverage refusals:

Controlled Substances Act (CSA) and the hemp carve‑out

The 2018 Farm Bill removed “hemp” from the CSA definition of marijuana, but only if the material contains no more than 0.3% delta‑9 THC on a dry‑weight basis. USPTO’s cannabis/hemp examination framework is summarized in USPTO Examination Guide 1‑19.

In practice, applicants often learn the hard way that “hemp‑derived” marketing language is not enough. The USPTO typically expects the identification of goods to be drafted so the goods are federally lawful on their face.

FDA/FD&C Act: the bigger obstacle for ingestible CBD (and often THC) beverages

Even when a product fits the hemp definition under the CSA, the FDA position on adding CBD or THC to food and beverages creates significant trademark risk.

FDA continues to issue enforcement communications reflecting its view that it is unlawful under the FD&C Act to introduce into interstate commerce foods to which CBD or THC has been added (subject to limited exceptions). See, for example, FDA warning letters like Holista LLC (Apr. 7, 2025), which cites FD&C Act restrictions on introducing certain cannabinoid-containing foods into interstate commerce.

The USPTO has incorporated FDA illegality reasoning in refusals for ingestible goods, including in office actions that expressly cite per se FD&C Act violations and TTAB precedent. For example, see the USPTO office action document for KIKOKO GOGO (Nov. 7, 2025) posted in the USPTO system: Serial No. 98326933 Office Action (PDF).

What this means for CBD and hemp‑THC beverage brands (2025–2026 reality)

From a brand strategy standpoint, you should assume:

• Many CBD beverage applications remain vulnerable at the USPTO because ingestible CBD is still entangled in FD&C Act restrictions.
• Intoxicating hemp‑THC beverages face additional risk because (i) legality varies widely by state, (ii) intoxicating positioning increases scrutiny, and (iii) product formulas or serving sizes can push beyond what regulators view as compliant.
• Even where a product is arguably lawful, the application record (website screenshots, label claims, product descriptions) can trigger a refusal.

Separately, beverage companies operating near alcohol-regulated channels must also watch federal alcohol regulators’ boundaries around bonded premises and production. Industry compliance analyses emphasize strict separation when producing non‑alcohol beverages with hemp cannabinoids from federally bonded alcohol operations. (For a compliance overview, see CannabisRegulations.ai’s discussion of TTB boundaries: Breweries and THC Drinks in 2025.)

Madrid Protocol 101 for beverage brands: why “file abroad first” can be rational

The Madrid System (Madrid Protocol) lets you seek trademark protection in multiple member jurisdictions through a single international registration, based on a basic application or registration in an “Office of origin.” WIPO explains the filing and examination flow here: WIPO Madrid System basics.

For beverage brands dealing with U.S. lawful-use risk, an international-first mindset can make sense:

• If your U.S. filing is likely to be refused for the core beverage goods, you may still want early protection in markets where your beverage is lawfully sold.
• A foreign filing can support distribution, licensing, and investment, even while U.S. federal registration is delayed.
• If your “home” filing is in the U.S., a Madrid international registration remains linked to that basic filing for the first five years (the “central attack” risk). So some companies consider building a stronger base in another jurisdiction where the goods are registrable (discuss with counsel).

Important: Madrid is not a magic bypass. Each designated country still performs its own substantive examination. If the product is not legal or the mark is misleading in a destination market, you can still get refused.

Building a practical Madrid strategy for CBD and hemp‑THC drinks

A workable approach in 2025–2026 often looks like a portfolio, not a single filing.

1) Separate your “brand” mark from your “beverage” goods risk

Consider filing multiple applications, each mapped to different risk levels:

• A core brand mark for ancillary goods/services that are clearly lawful in the U.S. (e.g., apparel; non‑downloadable educational content; certain software platforms; retail store services that are carefully described).
• A separate application (or foreign filings) for the actual beverage product in jurisdictions where that beverage is permitted.

This helps prevent a single unlawful-use issue from destabilizing the rest of your trademark portfolio.

2) Draft identifications to avoid accidental admissions

Many refusals start with the wording in the identification:

• Avoid language that implies unlawful ingredients, unlawful concentration, or unlawful intended use.
• For hemp-derived products, applicants often use limiting language consistent with the Farm Bill threshold (e.g., “containing hemp-derived cannabinoids with a delta‑9 THC concentration of not more than 0.3 percent on a dry weight basis”)—but remember: this does not automatically solve FDA ingestible issues.

3) Choose Madrid designations that match real commercialization plans

International filings are most valuable when aligned to:

• where you can lawfully sell the product,
• where you plan to manufacture/bottle,
• where counterfeiting risk is high.

For CBD foods and beverages in Europe, also account for “novel food” friction. Many jurisdictions treat CBD as a novel food requiring authorization before lawful marketing, creating not only regulatory risk but also trademark “use” and enforcement complications. A useful high-level reference point is the EU/UK “novel food” compliance discussion, such as the UK Food Standards Agency CBD guidance and public list process: FSA CBD guidance and the July 2025 FSA update on reformulation and labeling advice: FSA news alert (July 2025).

Canada is a different model: ingestible products containing THC are regulated under the Cannabis Act framework with strict packaging and labeling rules. For brand teams, that means trademark specimens and actual marketplace use must be compatible with mandatory warnings, standardized symbol, and label content requirements. See Health Canada’s packaging and labeling guide: Packaging and labelling guide.

Specimens: the most underestimated failure point for beverage marks

Even when you’ve navigated lawful-use issues, specimen problems can still sink an otherwise good application.

For goods (like beverages), the USPTO expects specimens showing the mark on:

• the product label,
• packaging,
• or a point-of-sale display where the goods can be purchased.

USPTO guidance on specimens and common refusals is here: Specimen refusal (USPTO) and Drawings and specimens (USPTO).

Specimen issues that show up constantly in beverage filings

“Mockups” and digitally altered labels

If the image looks like a marketing mockup (perfect lighting, generic bottle template, inconsistent shadows), examiners may request more information or refuse. Keep:

• dated production photos,
• invoices,
• shipping documentation,
• screenshots with URLs and access dates.

Website pages that don’t enable ordering

A page that only describes a drink may not qualify. USPTO typically wants a display associated with the goods that includes ordering information (price, add-to-cart, etc.) or other point-of-sale indicia.

Specimens that create lawful-use problems

This is the trap within the trap. A specimen can inadvertently:

• show dosing claims,
• show unlawful ingredient statements,
• show shipping claims into jurisdictions where sales are prohibited,
• imply drug/therapeutic effects.

Once those facts are in the record, it becomes harder to walk back a lawful-use refusal.

Labels, language, and customs: international “use” must match destination rules

International trademark protection is only as strong as your ability to prove valid use (where required) and to enforce without your own packaging becoming evidence of noncompliance.

Key cross-border considerations for beverages include:

Mandatory symbols and warnings

Some markets require standardized symbols, specific health warnings, or child-resistant features. If your label design cannot accommodate them without distorting the mark, you may need to:

• register a standard character version and a special form logo separately,
• or maintain approved lockups per jurisdiction.

Language requirements

If a destination requires warnings in multiple languages, be careful that translations do not:

• change the commercial impression,
• introduce descriptive or misleading wording,
• conflict with your brand guidelines.

“Suggestive” marks that imply illegal goods

Marks that explicitly reference getting “high,” drug slang, or illegal use may be registrable in some contexts but can become a practical barrier internationally—especially if regulators view the branding as promoting misuse or youth appeal.

Use Madrid to expand—but don’t ignore U.S. brand protection options

Even if your U.S. federal registration for the beverage itself is delayed, brands commonly layer protection:

1) State trademark registrations

State registrations can support enforcement within a state’s borders. They are not a substitute for federal registration, but they can be useful tactically.

2) Common law rights through consistent, documented use

Maintain strong proof of use:

• dated label runs,
• distributor agreements,
• purchase orders,
• marketing campaigns,
• consumer reviews tied to real sales.

3) Registrations for collateral classes

Many beverage companies protect their marks on:

• non‑cannabinoid beverages (where truthful),
• glassware, bar tools, and merchandise,
• software and downloadable content,
• entertainment or education services.

The goal is to secure enforceable rights while the regulatory path for ingestible cannabinoids in the U.S. remains unsettled.

Watch and enforcement program: keep your rights strong across jurisdictions

Trademark rights are not “set and forget,” particularly in high-growth beverage categories.

Build a watch program

A watch program can monitor:

• confusingly similar marks in key classes,
• copycat packaging,
• domain names and social handles.

Control licensees (or your use may become invalid)

If you license your brand to bottlers or distributors, ensure the license covers:

• quality control standards,
• packaging/label compliance in each market,
• approved claims and advertising,
• recordkeeping.

Weak control can jeopardize trademark validity and complicate enforcement.

Add border tools where available

If you obtain a U.S. federal registration, consider U.S. Customs recordation to help block counterfeit imports. CBP describes the IP recordation portal here: CBP Intellectual Property Rights e‑Recordation.

Compliance-driven takeaways for 2025–2026

• Plan for U.S. lawful-use scrutiny if your filing touches ingestible CBD or hemp‑THC beverages.
• Don’t let specimens sabotage you: they must show real use, and they must not create evidence of illegality or misleading claims.
• Use Madrid strategically: designate jurisdictions where the beverage is lawful and commercially important, but remember each country examines under its own rules.
• Consider a portfolio approach: protect the core brand via ancillary goods/services in the U.S. while pursuing beverage protection abroad.
• Align labels with destination requirements to preserve registrability and enforceability.

Next steps

If you’re building a beverage brand in this category, your trademark roadmap should be built alongside your cannabis compliance and product regulatory roadmap—especially around labeling, claims, testing documentation, distribution channels, and cross-border shipping.

Use https://cannabisregulations.ai/ to monitor regulatory changes, map packaging/label requirements by jurisdiction, and strengthen your compliance program so your trademark “use” stays defensible as laws evolve.